Tests a risk-based screening method for prostate cancer across Europe
Studies a risk-based method to find prostate cancer early in men.
Key facts
- Who runs it
- European Association of Urology Research Foundation
- Where
- Dublin, IrelandSee the siteAlso in 3 other countries, 4 sites
- Trial code
- Registry title
- Prostate Cancer Awareness and Initiative for Screening in the European Union
- Status
- Enrolling by invitation
- People taking part
- 20,000 people, planned
- Started
- 1 Jun 2024
- Planned end
- 1 Apr 2026
- Type of study
- Observational, 5 groups
- Treatments tested
- Risk-based screening algorithm
- Record updated
- 15 August 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men aged 50 to 69 who have never had prostate cancer. It tests a risk-based screening approach.
- Age
- 50 to 69 years
- Sex
- Men only
- Earlier treatment
- No previous diagnosis of prostate cancer. No prostate biopsy or MRI in the past six months.
Main reasons for not taking part
- Previous diagnosis of prostate cancer
- Unable to give written informed consent
- Prostate biopsy or MRI within the past six months
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Age 50-69 years old
Who cannot take part
- Previous diagnosis of prostate cancer
- Unable to provide written informed consent
- Had prostate biopsy or MRI within the past six months
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 69 years old?
Where in Ireland
Also in 3 other countries, 4 sites
- University College DublinDublin, IrelandNo longer taking part
About the trial
What the trial wants to find out
PRAISE-U was initiated on the 1st of April 2023 and is set to last for three years. This collaborative effort involves 25 institutions across 12 countries, all driven by a shared objective: to rationalize prostate cancer screening in Europe and enhance patient outcomes. PRAISE-U advocates for EU member states to offer exceptional clinical standards, incorporating cutting-edge personalized approaches to enable timely detection of prostate cancer in individuals who can benefit from early treatment. To assess the functionality, feasibility, and long-term viability of a risk-based algorithm, the consortium will collaborate with pilot sites in Spain, Poland, Ireland, and Lithuania.
The 5 groups in the trial
- Manresa, Spain
The pilot is run by the Althaia Foundation, driven by the director of primary care.
Treatment: Risk-based screening algorithm
- Region Galicia, Spain
The pilot is run by the Galician Healthcare Service (SERGAS), publicly funded healthcare system of Galicia, Spain.
Treatment: Risk-based screening algorithm
- Ireland
The pilot is run by the Health Service Executive, with University College Dublin as the academic institutional partner, in full support of the National Cancer Control programme (NCCP) and the National Screening Service (NSS) in Ireland
Treatment: Risk-based screening algorithm
- Poland
The pilot is run by the Lower Silesian Oncology, Pulmonology and Haematology Center. Subdivision of Urology with support from the National Institute of Public Health.
Treatment: Risk-based screening algorithm
- Lithuania
The pilot is run by the National Cancer Institute, where residents of the capital Vilnius region are served.
Treatment: Risk-based screening algorithm
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Prostate Cancer Awareness and Initiative for Screening in the European Union
- Plain-language title
- Tests a risk-based screening method for prostate cancer across EuropeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06424275, who can take part
- Publications
- Record updated
- 15 August 2025